versión impresa ISSN 0256-9574
SAMJ, S. Afr. med. j. v.102 n.3 Cape Town mar. 2012
Voluntary male medical circumcision
Matthew Kesinger; Peter S Millard
The thoughtful editorial by Professor Ncayiyana concerning the national circumcision programme in South Africa1 rests on two central arguments: first, that the scientific evidence is insufficient to justify such 'serious energy, money and resources', particularly when circumcision programmes have the potential of diverting money from other more effective interventions; and second, that risk compensation (the potential increase in risky behaviour after circumcision) may nullify any benefits of circumcision.
The scientific evidence
There are few medical or public health interventions that are based upon evidence as strong and consistent as that for the effectiveness of male circumcision in preventing female-to-male transmission of HIV. Ncayiyana reviews the cumulative evidence from early observational studies, and from the three landmark randomised controlled trials in Africa. He notes that the studies were stopped early. However, they were not stopped early by investigators; individual studies were stopped by their independent Data and Safety Monitoring Board because the evidence was strong enough to deem unethical the withholding of circumcision from the control group. All men were then offered circumcision and, as Ncayiyana points out, an opportunity for direct long-term follow-up was lost. However, not all was lost. Observational research continues to strengthen the experimental findings. For example, a community-based survey of the Orange Farm community was recently presented, which showed an increase in circumcision coverage from 15.6% in 2007 to 49.4% in 2010, with a concomitant HIV seroprevalence of 20% among uncircumcised men and 6.2% among circumcised men, and no correlation between circumcision status and sexual behaviour.2
Risk compensation - does it exist?
Ncayiyana argues that circumcision may increase risk compensation and therefore increase HIV transmission. The Orange Farm trial did indeed find a slight increase in risky behaviour in the circumcised men, but, in spite of this, there was a still 60% reduction in HIV transmission.3 On the other hand, the Uganda trial 'did not find evidence that men in the intervention group adopted higher sexual risk behaviours than those in the control group. This could have been due to the intensive health education provided during the trial to minimise risk compensation.'4
The Kenyan trial found that 'the differences (of risk behaviour) between the two groups are attributable to increases in safer sexual practices in the control group rather than to riskier behaviour patterns in the circumcision group, indicating that risk compensation did not occur during the 24 months of this study'.5 In fact, condom use went up in both groups and unprotected sex went down in both. This is probably a function of intensive counselling. Further studies in the Kenyan cohort and community show that risk compensation is not a necessary consequence and that circumcision can be used as an opportunity to educate men about HIV prevention.6-8
Most importantly in relation to South Africa, Ncayiyana cites a survey by Bridges et al. claiming that this study links demand for circumcision with the idea that a circumcised man no longer needs to use a condom.9 But the results of this study are: 'Johannesburg, South Africa, shows that demand for circumcision is largely determined by the perceived benefits of reduced HIV/STI transmission risk, better hygiene and better sex ... [O]ur analysis shows that - in the aggregate - condom avoidance is not perceived as a benefit of circumcision. Our findings suggest that moral hazard concerns related to risk compensation via condom avoidance associated with male circumcision are exaggerated.'9
Cost and impact of circumcision
Finally, Ncayiyana compares the HIV epidemic in South Africa with Australia and the USA, stating that Australia does not recommend universal circumcision, and that it therefore is not right for South Africa. There are very different drivers for the HIV epidemic in South Africa versus Australia, and comparing them is unwise. In Australia, for example, 100 cases of heterosexually transmitted HIV are diagnosed annually.10 On the other hand, in South Africa about 1 400 new HIV infections occur per day, almost all via heterosexual transmission.11 And despite the relatively high rate of heterosexual transmission (31%) in the USA, the seroprevalence rate is 0.4% and the major route of transmission is men who have sex with men,12 which is certainly not the case in South Africa.
The high heterosexual transmission rate in South Africa means that the number of men who must be circumcised to prevent one HIV infection is much lower than in the USA or Australia. UNAIDS and the World Health Organization (WHO), using South African data and heterosexual transmission models, estimate that one new HIV infection can be avoided for every 5 to 15 circumcisions.13 And this estimate takes into account possible risk compensation across the entire population.
Large-scale circumcision will consume resources, energy and time, but, as Hillary Clinton said, 'we all must step up our use of combination prevention'.14 Because the impact of circumcision is so much greater in South Africa, scaling up circumcision is much more cost-effective compared with other countries. The cost savings in HIV prevention in high-prevalence areas is estimated at between US$150 and nearly $900 per infection prevented over a 10-year time horizon.13 If 1 000 adult males were circumcised in South Africa's Gauteng province alone, $2.4 million could potentially be saved in HIV treatments over 20 years.15 The money saved on treatment could be reinvested in testing, treatment, and prevention of vertical transmission - other methods of prevention that Ncayiyana points out have a proven impact.
1. Ncayiyana DJ. The illusive promise of circumcision to prevent female-to-male HIV infection - not the way for South Africa. S Afr Med J 2011;101:775-777. [ Links ]
2. Auvert B, Taljaard D, Rech D, et al. Effect of the Orange Farm (South Africa) male circumcision rollout (ANRS-12126) on the spread of HIV. 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. http://pag.ias2011.org/Abstracts.aspx?AID=4792 (accessed 1 December 2011). [ Links ]
3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2(11):e298. [doi:10.1371/journal.pmed.0020298] [ Links ]
4. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-666. [ Links ]
5. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-656 [ Links ]
6. Agot KE, Kiarie JN, Nguyen HQ, Odhiambo JO, Onyango TM, Weiss NS. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral 7. disinhibition following circumcision. J Acquir Immune Defic Syndr 2007;44:66-70. [ Links ]
7. Riess TH, Achieng' MM, Otieno S, Ndinya-Achola JO, Bailey RC. When I was circumcised I was taught certain things: Risk compensation and protective sexual behavior among circumcised men in Kisumu, Kenya. PLoS One 2010;5(8):e12366. Published online 2010 August 25. [doi: 10.1371/journal. pone.0012366] [ Links ]
8. Westercamp M, Bailey RC, Bukusi EA, Montandon M, Kwena Z, Cohen CR. Male circumcision in the general population of Kisumu, Kenya: beliefs about protection, risk behaviors, HIV, and STIs. PLoS One 2010; 5(12):e15552. [ Links ]
9. Bridges JFP, Selck FW, Grey GE, et al. Condom avoidance and determinants of demand for male circumcision in Johannesburg, South Africa. Health Policy Plan 2011;26(4):298-306. [doi: 10.1093/ heapol/czq064] [ Links ]
10. Parish M. UNGASS Country Progress Report Australia 2010. UNAIDS.org. http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/Australia_Narrative_Report_2009.pdf (accessed 1 December 2011). [ Links ]
12. CDC HIV/AIDS Factsheets. Male circumcision and risk for HIV transmission and other health conditions: Implications for the United States 2008. http://www.cdc.gov/hiv/resources/factsheets/circumcision.htm (accessed 1 December 2011). [ Links ]
13. Hankins C. UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention. Male circumcision for HIV prevention in high HIV prevalence settings: What can mathematical modelling contribute to informed decision making? PLoS Med 2009;6(9):e1000109. [doi:10.1371/journal.pmed.1000109] [ Links ]
14. Vlosky, I. ThinkProgress.org. http://thinkprogress.org/health/2011/11/08/363926/hillary-clintoncommits-us-government-to-ushering-in-an-aids-free-generation/ (accessed 1 December 2011). [ Links ]
15. Khan J, Marseille, E, Auvert, B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. Published online 2006 December 26. [doi: 10.1371/journal.pmed.0030517] [ Links ]
The authors have no conflict of interest.
This work was funded in part by a grant from the Fogarty International Center, NIH (grant 3 D43 TW01038) to the University of Pittsburgh.
Matthew Kesinger is an MD candidate at the University of Pittsburgh, PA, USA. Peter Millard, MD, PhD, is a professor at the Catholic University of Mozambique Faculty of Health Sciences.
Corresponding author: M Kesinger (firstname.lastname@example.org)